CSI Market
Sign In | Register

Aimmune Therapeutics Inc (AIMT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access AIMT quarterly Cash Flow →
Cash flow patterns shown here provide context for understanding Aimmune Therapeutics Inc's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2019)
12 Months 		(Dec 31 2018) (Dec 31 2017) (Dec 31 2016) (Dec 31 2015)
Operating Activities
Income-248.50
Depreciation & amortization4.09
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation32.93
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Investment Income Net Amortization Of Discount And Premium-1.63
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable6.20
Increase (Decrease) in Accrued Liabilities2.04
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets3.89
Other Working Capital0.95
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities4.63
Discontinued operations0.00
Net Cash flow from Operating Activities-195.41
Investing Activities
Capital Expenditures-8.05
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Available-for-sale Securities, Debt-166.32
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments286.27
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities111.90
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-3.86
Long-term debt - borrowings40.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock20.41
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.67
Capital Lease Obligations Incurred-
Proceeds From Issuance Of Preferred Stock And Common Stock-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities55.88
Effect of exchange rate on cash flow-27.63
Discontinued operations0.00
Free Cash Flow-203.45
Total Cash Flow-27.63
4 historic quarters locked

Sign in to unlock the full Aimmune Therapeutics Inc cash flow history.

Sign In Create Free Account

About AIMT Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License